Regulatory Capture

Who Is to Blame for the 2008 Financial Crisis?

The IGM Center at the University of Chicago has asked its American and European economist panel to rate the main causes of the financial...

Bo Rothstein Explains Why He Resigned From Oxford Over Donor's Link to Donald Trump

In an interview with ProMarket, Swedish political scientist Bo Rothstein explains why he decided to resign from the Blavatnik School of Government after learning...

Call for Proposals: 10th Anniversary of the Global Financial Crisis

The Initiative on Global Markets (IGM) and the Stigler Center are organizing a conference on the causes, as well as the key players and...

Bribery, Cooperation, and the Evolution of Prosocial Institutions

How the science of cooperation and cultural evolution will give us new tools in combating corruption.     There is nothing natural((Putting aside what it means for...

Eliot Spitzer: The Democratic Party Has Become the Party of the Status Quo

Former New York governor Eliot Spitzer talks about antitrust, digital platforms, economic concentration, and regulatory capture. Part 2 of 2.      In the first part of...

Eliot Spitzer: The U.S. Never Had the Will and the Ability to Hold the Most Powerful to Account

In a special interview with ProMarket, former New York governor Eliot Spitzer talks about financial regulation, regulatory capture, and antitrust. Part 1 of 2.   Clear rules and...

How Biology Explains Back-Scratching Between Wall Street and Government

The revolving door of government and business explained in the lab. The systemic financial risk-taking in the lead-up to the financial crisis was a product...

"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"

In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...

When Medical Experiments Serve the Business Needs of Pharmaceutical Firms Instead of Science

The first part of a two-part interview with Daniel Goldstein, MD, an oncologist who also studies the influence of business interests on healthcare—from treating patients...

Big Four Audit Firms Enjoy a “Too Few to Fail” Regulatory Hall Pass

The failure of Enron and subsequent demise of Arthur Andersen led to significant changes for public reporting and auditing but not much change in...

Latest news